E-Mail
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows.
Researchers say that while these instances are rare, doctors should be aware of this potential complication. The study, published in the April 26 online issue of the
Journal of the American College of Cardiology, may prompt more monitoring of heart failure symptoms among patients hospitalized with COVID-19. This is one of the largest studies to date to specifically capture instances of new heart failure diagnosis among patients hospitalized with COVID-19. While rare, the finding of new heart failure was more common among patients with preexisting cardiovascular risk factors or disease. But there were select individuals who developed new heart failure without risk factors or disease. We need to learn more about how SARS-CoV-2 [the virus that causes COVID-19] may direc
April 23, 2021
The Valve Academic Research Consortium (VARC) has updated their standardized definitions of clinical endpoints for transcatheter and surgical aortic valve clinical trials, including bioprosthetic valve dysfunction and failure, structural complications, conduction disturbances, and repeat hospitalizations, among others.
Published this week in the
European Heart Journal and the
Journal of the American College of Cardiology, the VARC-3 update was adopted given the “rapid evolution of the field,” including the emergence of new complications, expanding clinical indications, and novel therapy strategies, according to the writing committee.
As aortic valve research moves into younger patients, as well as those with less advanced aortic stenosis, future trials be they head-to-head comparisons of TAVI devices, TAVI versus surgery, or even TAVI or surgery versus medical therapy will need standardized definitions for capturing appropriate endpoints, the authors stre
11 Best Sugar-Free Sodas on Grocery Store Shelves msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and .
Amarin Corporation plcApril 22, 2021 GMT
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication
1,2,
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor
Long Work Hours Linked to High Rate of Repeat Heart Attack theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.